Anzeige
Mehr »
Login
Freitag, 29.03.2024 Börsentäglich über 12.000 News von 687 internationalen Medien
NurExone Biologic: Technisches (täglich, wöchentlich, monatlich) & Analysten "Strong Buy"-Rating!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
GlobeNewswire
223 Leser
Artikel bewerten:
(0)

Grindeks: On "Grindeks" results in 2017

Turnover of "Grindeks" reaches 132.4 million euro in 2017; profit - 10.3
million euro
Today, on 28 February, the JSC "Grindeks" submitted the non-audited
consolidated financial statements of 2017 to "Nasdaq Riga". Non-audited
financial results indicate that in 2017 turnover of the Group was 132.4 million
euro and has increased by 27 million euro or 26% in comparison to 2016. In
2017, the Group's net profit, attributable to shareholders of the parent
company, was 10.3 million euro and has increased by 0.8 million euro or 8%
compared to 2016. Gross profit margin in 2017 was 57%, while net profit margin
was 8%. In 2017, the Group's production was exported to 77 countries worldwide,
a total of 122.4 million euro which is by 27.2 million euro or 28% more than in
2016. 

At the end of the reporting period the amount of accounts receivable (debtors)
was 63.7 million euro, which is by 22.4 million euro more than accounts payable
(liabilities) that were 41.3 million euro. The amount of current assets at the
end of reporting period was 92.2 million euro, which is by 67.1 million euro
more than amount of current liabilities which was 25.1 million euro. 

The Chairman of the Board of JSC "Grindeks" Juris Bundulis: "The dynamic
increase approves "Grindeks" is now on a wisely chosen and stable course of
strategic development, based on strengthening existing positions in the current
markets as well as successful expansion into new regions. In 2018, additionally
to our traditional markets we are motivated to proceed with business
development in the EU countries, where the turnover of nearly 20 million euro
in 2017 was already achieved, and as before, we will continue entering
Southeast Asia markets." 

Sales volume of the final dosage forms of "Grindeks" in 2017 was 124.2 million
euro and has increased by 27.2 million euro or 28% in comparison to 2016. In
2017, the sales amount in Russia, the other CIS countries and Georgia reached
81.1 million euro, which is by 23 million euro or 39% more than in 2016. In
comparison to 2016, the biggest increase in sales volume has been reached in
Tajikistan (69%), Russia (53%), Ukraine (40%), Armenia (35%), Azerbaijan (34%)
and Kirgizstan (34%). 

In 2017, the sales volume in the Baltic States and other countries reached 43.1
million euro which is by 4.2 million euro or 11% more than in 2016. In 2017,
the sales volume compared to 2016 in Slovakia has increased by 4.3 times,
Australia by 3.6 times, Albania by 93%, France by 90%, Spain by 63%, Sweden by
60%. In 2017, the sales volume in Latvia reached 7.4 million euro and has
increased by 0.1 million euro or 2% in comparison to 2016. Increase in sales
has been reached also in the other Baltic States - in Lithuania by 13% and
Estonia by 6%. 

In 2017, sales of the active pharmaceutical ingredients reached 6.9 million
euro, which is by 0.6 million euro or 9% more than in 2016. During the
reporting period the majority of "Grindeks" active pharmaceutical ingredients
were exported to the EU countries, Canada, Australia and Japan. The most
required active pharmaceutical ingredients of "Grindeks" in 2017 were
zopiclone, oxytocin, pimobendan, medetomidin, ftorafur (tegafur) and xylazine. 

The Chairman of the Council of JSC "Grindeks" Kirovs Lipmans: "From the
perspective of company's shareholders "Grindeks" showed a great performance in
2017. Especially, a notable growth of Group's value, improvements in overall
cash flow and remarkably reduced accounts receivable have to be highlighted. We
are expecting stable growth to proceed in 2018 with at least 10% rise in
turnover, while to meet the growing demand we will invest at least 7 million
euro to raise production capacity in Group's manufacturing facilities in
Latvia, Estonia and Slovakia. In the name of the company's council and
shareholders I am thankful to "Grindeks" team for last year's performance." 

About "Grindeks"

"Grindeks" is an international pharmaceutical company focused on research,
development, manufacturing and sales of original products, generics and active
pharmaceutical ingredients. The Group of "Grindeks" has five subsidiary
companies in Latvia, Estonia, Russia and Slovakia as well as representative
offices in 12 countries. 

"Grindeks" specializes in the heart and cardiovascular, CNS, anti-cancer and
gastroenterological medication therapeutic groups. A range of products covers a
combination of original products Mildronate (meldonium*) and Ftorafur,
generics, food supplements and active pharmaceutical ingredients. 

In 2017 products of the company were exported to 77 countries with export
comprising 92.5% of the total turnover. The key markets include the EU
countries, Russia and the other CIS countries, the U.S., Canada, Japan and
Vietnam. 

To increase production capacity and develop infrastructure, the company has
accomplished many significant investment projects, investing around 100 million
euros over the last 15 years. 

*Notice: meldonium is included in the list of substances prohibited in sport.

         Further information:
         Laila Klavina
         Head of the Communications Department, JSC "Grindeks"
         Phones: (+371) 67083370, (+371) 29256012
         Fax: (+371) 67083505
         laila.klavina@grindeks.lv

Attachment:
https://cns.omxgroup.com/cds/DisclosureAttachmentServlet?messageAttachmentId=666051
Großer Dividenden-Report 2024 von Dr. Dennis Riedl
Der kostenlose Dividenden-Report zeigt ganz genau, wo Sie in diesem Jahr zuschlagen können. Das sind die Favoriten von Börsenprofi Dr. Dennis Riedl
Jetzt hier klicken
© 2018 GlobeNewswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.